Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1720

Sort by

Sort Order Select

Journal Articles

Phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia

Blood blood.2025030722.

https://doi.org/10.1182/blood.2025030722

Published: 2026

Includes: Supplemental data

Journal Articles

Ultraprecision Therapy for Type 1 vs Type 2 CALR+ MPN by Dual Epitope Targeting that Restores Ruxolitinib Sensitivity

Blood blood.2024027897.

https://doi.org/10.1182/blood.2024027897

Published: 2026

Includes: Supplemental data

Journal Articles

A Stem and Progenitor Cell-Derived Gene Expression Signature is Prognostic for Survival in Myelofibrosis

Blood blood.2025030094.

https://doi.org/10.1182/blood.2025030094

Published: 2026

Includes: Supplemental data

Journal Articles

Advancing the Classification of Hematolymphoid Neoplasms Together: For Patients, Medicine, and Science

Robert P Hasserjian, Joseph D. Khoury, Carlos E. Bueso-Ramos, Stefan Dirnhofer, Dilani Lokuhetty, Maurilio Ponzoni

Blood blood.2025030689.

https://doi.org/10.1182/blood.2025030689

Published: 2026

Journal Articles

Mechanisms of immune escape and extramedullary tropism in leukemia cutis

Livius Penter, Katie Maurer, Nicoletta Cieri, Wesley S. Lu, Haoxiang Lyu, Mischa Selig, Maria Joosten, Jana Ihlow, Shuqiang Li, Kenneth J. Livak, Lars Bullinger, Jerome Ritz, Pavan Bachireddy, Matthew S. Davids, Jacqueline S. Garcia, Robert J. Soiffer, Catherine J. Wu

Blood (2026) 147 (1): 35–47.

https://doi.org/10.1182/blood.2025029121

Published: 2026

Includes: Supplemental data

Journal Articles

Measurable residual disease intervention in AML: a new therapeutic horizon

Andrew H. Wei, Harry J. Iland, Courtney D. DiNardo, John Reynolds

Blood (2026) 147 (1): 13–23.

https://doi.org/10.1182/blood.2025029010

Published: 2026

Journal Articles

Fetal context conveys heritable protection against MLL-rearranged AML that depends on MLL3

Jonny Mendoza-Castrejon, Wei Yang, Elisabeth Denby, Helen C. Wang, Emily B. Casey, Rohini Muthukumar, Riddhi M. Patel, Jihye Yoon, Yanan Li, J. Michael White, Ran Chen, Luis F. Z. Batista, Jeffrey A. Magee

Blood (2026) 147 (1): 61–72.

https://doi.org/10.1182/blood.2025029686

Published: 2026

Includes: Supplemental data

Journal Articles

CD371-targeted CAR T cells secreting interleukin-18 exhibit robust expansion and clear refractory acute myeloid leukemia

Blood (2025) 146 (26): 3163–3174.

https://doi.org/10.1182/blood.2025029532

Published: 2025

Includes: Supplemental data

Journal Articles

Genome-wide analysis defines genetic determinants of MPN subtypes and identifies a sex-specific association at CDH22 / CD40

Blood (2025) 146 (26): 3228–3233.

https://doi.org/10.1182/blood.2025028489

Published: 2025

Includes: Supplemental data

Journal Articles

CEBPA repression by MECOM blocks differentiation to drive aggressive leukemias

Blood (2025) 146 (25): 3019–3035.

https://doi.org/10.1182/blood.2025028954

Published: 2025

Includes: Supplemental data

Journal Articles

MECOM is a master repressor of myeloid differentiation through dose control of CEBPA in acute myeloid leukemia

Dorien Pastoors, Marije Havermans, Roger Mulet-Lazaro, Leonie Smeenk, Sophie Ottema, Claudia Erpelinck-Verschueren, Stanley van Herk, Maikel Anthonissen, Tim Grob, Shruthi Subramanian, Julie A. I. Thoms, John E. Pimanda, Bas J. Wouters, Berna Beverloo, Torsten Haferlach, Claudia Haferlach, Johannes Zuber, Eric Bindels, Ruud Delwel

Blood (2025) 146 (25): 3098–3105.

https://doi.org/10.1182/blood.2025028914

Published: 2025

Includes: Supplemental data

Journal Articles

The role of CD38 in monocytes during fibrotic progression of myeloproliferative neoplasms

Yiru Yan, Jinqin Liu, Songyang Zhao, Fuhui Li, Lin Yang, Zefeng Xu, Tiejun Qin, Xiaofan Zhu, Wenbin An, Zhongxun Shi, Wenyi Shen, Peihong Zhang, Gang Huang, Raajit K. Rampal, Zhijian Xiao, Bing Li

Blood blood.2025028703.

https://doi.org/10.1182/blood.2025028703

Published: 2025

Includes: Supplemental data

Journal Articles

The glycosaminoglycan oncofetal chondroitin sulfate represents a novel target for antibody drug-conjugate therapy for AML

Blood blood.2024028147.

https://doi.org/10.1182/blood.2024028147

Published: 2025

Includes: Supplemental data

Journal Articles

Pharmacological Inhibition of miR-126 Enhances Venetoclax Activity in Acute Myeloid Leukemia

Blood blood.2025029875.

https://doi.org/10.1182/blood.2025029875

Published: 2025

Includes: Supplemental data

Journal Articles

2025 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the ELN-DAVID MRD Working Party

Blood blood.2025031480.

https://doi.org/10.1182/blood.2025031480

Published: 2025

Includes: Supplemental data

Journal Articles

Microenvironmental cell interactions are essential for sustaining functionality of myelofibrosis malignant stem cells

Min Lu, Md. Babu Mia, Lijuan Xia, Gohar Mosoyan, Momina Hayat, Christoph Schaniel, Ronald Hoffman

Blood blood.2025031454.

https://doi.org/10.1182/blood.2025031454

Published: 2025

Includes: Supplemental data

Journal Articles

CUX1 restrains latent hematopoietic stem cell plasticity by suppressing stem cell–intrinsic inflammatory pathways

Tanner C. Martinez, Matthew R. M. Jotte, Saira Khan, Angela Stoddart, Hunter Blaylock, Ankit Malik, Megan E. McNerney

Blood (2025) 146 (24): 2914–2930.

https://doi.org/10.1182/blood.2024026815

Published: 2025

Includes: Supplemental data

Journal Articles

Fusion gene depletion eliminates stemness and induces bidirectional differentiation of acute myeloid leukemia

Polina K. Derevyanko, Laura E. Swart, L. Daniel Mata Casimiro, Anita van Oort, Manisha du Plessis, Luca van den Brink, Minoo Ashtiani, C. Michel Zwaan, Anja Krippner-Heidenreich, Constanze Bonifer, Raymond Schiffelers, Josef Vormoor, Sophie G. Kellaway, Olaf Heidenreich

Blood (2025) 146 (24): 2963–2978.

https://doi.org/10.1182/blood.2025028988

Published: 2025

Includes: Supplemental data

Journal Articles

Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial

Blood blood.2025030816.

https://doi.org/10.1182/blood.2025030816

Published: 2025

Includes: Supplemental data

Journal Articles

Impact of ASXL1 at diagnosis in patients with CML receiving frontline potent TKIs: high risk of kinase domain mutations

Blood (2025) 146 (23): 2821–2832.

https://doi.org/10.1182/blood.2025030259

Published: 2025

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia

Ultraprecision Therapy for Type 1 vs Type 2 CALR+ MPN by Dual Epitope Targeting that Restores Ruxolitinib Sensitivity

A Stem and Progenitor Cell-Derived Gene Expression Signature is Prognostic for Survival in Myelofibrosis

Advancing the Classification of Hematolymphoid Neoplasms Together: For Patients, Medicine, and Science

Mechanisms of immune escape and extramedullary tropism in leukemia cutis

Measurable residual disease intervention in AML: a new therapeutic horizon

Fetal context conveys heritable protection against MLL-rearranged AML that depends on MLL3

CD371-targeted CAR T cells secreting interleukin-18 exhibit robust expansion and clear refractory acute myeloid leukemia

Genome-wide analysis defines genetic determinants of MPN subtypes and identifies a sex-specific association at CDH22 / CD40

CEBPA repression by MECOM blocks differentiation to drive aggressive leukemias

MECOM is a master repressor of myeloid differentiation through dose control of CEBPA in acute myeloid leukemia

The role of CD38 in monocytes during fibrotic progression of myeloproliferative neoplasms

The glycosaminoglycan oncofetal chondroitin sulfate represents a novel target for antibody drug-conjugate therapy for AML

Pharmacological Inhibition of miR-126 Enhances Venetoclax Activity in Acute Myeloid Leukemia

2025 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the ELN-DAVID MRD Working Party

Microenvironmental cell interactions are essential for sustaining functionality of myelofibrosis malignant stem cells

CUX1 restrains latent hematopoietic stem cell plasticity by suppressing stem cell–intrinsic inflammatory pathways

Fusion gene depletion eliminates stemness and induces bidirectional differentiation of acute myeloid leukemia

Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial

Impact of ASXL1 at diagnosis in patients with CML receiving frontline potent TKIs: high risk of kinase domain mutations

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only